Thomas Kutner1, Emily Kunkel1, Yue Wang2, Kyle George1, Erik L Zeger1,3, Zonera A Ali1,3, George C Prendergast1, Paul B Gilman1,3, U Margaretha Wallon4. 1. Lankenau Institute for Medical Research, Lankenau Medical Center, Wynnewood, PA, 19096, USA. 2. Hematology/Oncology Fellowship Program, Lankenau Medical Center, Wynnewood, PA, 19096, USA. 3. Department of Medical Oncology, Lankenau Medical Center, Wynnewood, PA, 19096, USA. 4. Lankenau Institute for Medical Research, Lankenau Medical Center, Wynnewood, PA, 19096, USA. wallon@limr.org.
Abstract
PURPOSE: The aim of this study was to test a new blood-based assay for its ability to predict delayed chemotherapy-induced nausea. METHODS: Blood drawn from consented patients prior to receiving their first platinum-based therapy was tested for glutathione recycling capacity and normalized to total red cell numbers. This number was used to predict nausea and then compared to patient reported outcomes using the Rotterdam Symptom Check List and medical records. RESULTS: We show that the pathways involved in the glutathione recycling are stable for at least 48 h and that the test was able to correctly classify the risk of nausea for 89.1 % of the patients. The overall incidence of nausea was 21.9 % while women had an incidence of 29.6 %. CONCLUSIONS: This might be the first objective test to predict delayed nausea for cancer patients receiving highly emetogenic chemotherapy. We believe that this assay could better guide clinicians in their efforts to provide optimal patient-oriented care.
PURPOSE: The aim of this study was to test a new blood-based assay for its ability to predict delayed chemotherapy-induced nausea. METHODS: Blood drawn from consented patients prior to receiving their first platinum-based therapy was tested for glutathione recycling capacity and normalized to total red cell numbers. This number was used to predict nausea and then compared to patient reported outcomes using the Rotterdam Symptom Check List and medical records. RESULTS: We show that the pathways involved in the glutathione recycling are stable for at least 48 h and that the test was able to correctly classify the risk of nausea for 89.1 % of the patients. The overall incidence of nausea was 21.9 % while women had an incidence of 29.6 %. CONCLUSIONS: This might be the first objective test to predict delayed nausea for cancerpatients receiving highly emetogenic chemotherapy. We believe that this assay could better guide clinicians in their efforts to provide optimal patient-oriented care.
Entities:
Keywords:
Blood test; CINV; Delayed nausea; Predictive test
Authors: Catherine M Bender; Roxanne W McDaniel; Kathleen Murphy-Ende; Mary Pickett; Cynthia N Rittenberg; Miriam P Rogers; Susan M Schneider; Rowena N Schwartz Journal: Clin J Oncol Nurs Date: 2002 Mar-Apr Impact factor: 1.027
Authors: George Dranitsaris; Nathaniel Bouganim; Carolyn Milano; Lisa Vandermeer; Susan Dent; Paul Wheatley-Price; Jenny Laporte; Karen-Ann Oxborough; Mark Clemons Journal: J Support Oncol Date: 2013-03
Authors: Joseph A Roscoe; Gary R Morrow; Ben Colagiuri; Charles E Heckler; Bryan D Pudlo; Lauren Colman; Karen Hoelzer; Andrew Jacobs Journal: Support Care Cancer Date: 2009-08-23 Impact factor: 3.603
Authors: Steven M Grunberg; Robert R Deuson; Panagiotis Mavros; Olga Geling; Mogens Hansen; Giorgio Cruciani; Bruno Daniele; Gerard De Pouvourville; Edward B Rubenstein; Gedske Daugaard Journal: Cancer Date: 2004-05-15 Impact factor: 6.860
Authors: Jie Li; Donglan Zhang; Pearl A Jefferson; Kathleen M Ward; Iraimoudi S Ayene Journal: J Pharmacol Toxicol Methods Date: 2013-10-20 Impact factor: 1.950
Authors: Winnie Yeo; F K F Mo; J J S Suen; W M Ho; S L Chan; W Lau; J Koh; W K Yeung; W H Kwan; K K C Lee; T S K Mok; A N Y Poon; K C Lam; E K Hui; B Zee Journal: Breast Cancer Res Treat Date: 2008-03-10 Impact factor: 4.872